Looming patent cliffs and shrivelling pipelines have pharma's big players looking for new business models that will allow them to increase their bottom lines.
Editor’s Choice
The whole package
The financial crisis and increasing regulatory restrictions make the pharma industry a tough battleground. GSK's Keith Allen tells NGP why innovative processes in the manufacturing line and ensuring regulatory harmony will create the winners in the industry.
The push of pharmaceutical research and development
With patent expiries due on some of the industry's biggest-selling drugs, pharmaceutical research and development has never been so important to the industry. What's more, in just the last two weeks, a plethora of Big Pharma companies have executed dramatic R&D strategies, highlighting just how critical the process has become.
Are blockbuster drugs dead in the water?
Reports suggest that blockbuster drugs - defined as a drug that generates more than $1 billion of revenue each year - are beginning to wane. Are the reports true? And if so, how can pharma shift its focus to compensate potentially massive losses?
EFPIA fights back at counterfeit drugs
With counterfeit drugs becoming a very real problem for the pharmaceutical industry, EFPIA has announced Swedish trials of a new system aimed at combating the growth of this increasingly significant threat.
Changing times
Wyeth’s Thorir Bjornsson talks to NGP about dealing with attrition, the fallout from the merger with Pfizer, and what the future holds for the industry.
Source: www.ngpharma.eu.com© 2010 GDS Publishing Ltd. All rights reserved.